Surmodics, Inc.
NASDAQ Global SelectCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Gary R. Maharaj
- Full Time Employees
- 389
- Sector
- Healthcare
- Industry
- Medical - Devices
- Address
- 9924 West 74th Street Eden Prairie MN United States of America 55344-3523
- IPO Date
- Mar 4, 1998
- CIK
- 0000924717
- Website
- surmodics.com
- Similar Companies
- Business
- Surmodics, Inc. specializes in the development, manufacturing, and commercialization of surface modification technologies, drug delivery systems, and in vitro diagnostic (IVD) products primarily for the healthcare industry. The company offers proprietary performance coatings including surface modification coatings that enhance lubricity, biocompatibility, and device deployment for intravascular medical devices across neurovascular, peripheral, and coronary markets. Its drug delivery product line includes biodegradable polymer excipients for sustained, site-specific drug release from medical devices. Surmodics also markets a portfolio of advanced medical devices such as the 0.014 RX percutaneous transluminal angioplasty (PTA) balloon catheter and thrombectomy devices like the Pounce LP and Pounce XL systems designed for minimally invasive removal of thrombi. In the in vitro diagnostics segment, it supplies chemical and biological components, including reagents, antibodies, substrates, and bioactive polymers used to improve the performance and reliability of immunoassay and molecular diagnostic tests. Founded in 1979 and headquartered in Minnesota, USA, Surmodics operates globally with a focus on the medical device and diagnostic industries. The company has established strategic partnerships with major medical device and pharmaceutical companies including Abbott, Boston Scientific, and Medtronic, supporting the development and commercialization of advanced drug-coated balloons and surface technologies. Surmodics maintains a strong R&D program to innovate next-generation surface and drug delivery technologies, aiming to improve clinical outcomes for patients. Recent major developments include the 2023 acquisition of Sirius Medical, expanding its thrombectomy and vascular intervention capabilities. In 2024, Surmodics launched the Pounce LP and Pounce XL thrombectomy systems commercially following FDA clearance, targeting removal of thrombi in peripheral arteries. The company also launched the Preside hydrophilic coatings in late 2023 to enhance device performance. A major corporate change occurred in 2024 when Surmodics was acquired by GTCR, a private equity firm specializing in healthcare investments, taking the company private with a valuation of approximately $627 million. This acquisition positions Surmodics for continued growth and expansion in medical device coatings and IVD markets under new ownership. Surmodics reported fiscal 2024 revenue growth driven by medical device sales, including increased demand for its balloon catheters and thrombectomy products. The company is advancing clinical trials for its SurVeil™ drug-coated balloon platforms for peripheral artery disease, with plans for further commercialization and product pipeline expansion in the near term. Its product portfolio and strategic collaborations reinforce its role as a leading provider of innovative surface modification and drug delivery technologies designed to address unmet clinical needs and improve patient outcomes worldwide.
Brokerages Set Surmodics, Inc. (NASDAQ:SRDX) Target Price at $43.00
Groupe la Francaise Sells 33,700 Shares of Surmodics, Inc. $SRDX
Surmodics Announces FTC Does Not Intend to Appeal Denial of Injunction, Order Preventing Closing Set to Expire Today
Federal Judge Clears Path For GTCR's Takeover Of Surmodics After FTC Challenge
Surmodics Announces U.S. District Court Denies Request for Preliminary Injunction to Block Proposed Acquisition by GTCR
Surmodics Announces Outcomes from 160 Patients in PROWL Registry Evaluating Pounce™ Thrombectomy Platform in Treatment of Real-World Limb Ischemia Presentations
Surmodics Announces PROWL Registry 160-Patient Data to be Presented in Industry-Sponsored Session at VIVA Conference on November 3
SRDX Stock Up Following Q3 Earnings Beat, Gross Margin Contracts
SurModics (SRDX) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates
SurModics (SRDX) Q3 Earnings and Revenues Beat Estimates
Surmodics (SRDX) Q3 EPS Turns Positive
Surmodics Reports Third Quarter of Fiscal Year 2025 Financial Results; Updates Fiscal Year 2025 Financial Guidance
Why Is SurModics (SRDX) Up 6% Since Last Earnings Report?
SRDX Stock Down Following Q2 Earnings Miss, Gross Margin Contracts
SurModics (SRDX) Reports Q2 Earnings: What Key Metrics Have to Say
SurModics (SRDX) Reports Q2 Loss, Misses Revenue Estimates
Surmodics Reports Second Quarter of Fiscal Year 2025 Financial Results; Introduces Fiscal Year 2025 Financial Guidance
Surmodics to Report Second Quarter of Fiscal 2025 Financial Results on April 30
Surmodics Announces Publication of TRANSCEND Trial, Highlighting Drug-Delivery Technology of its SurVeil™ Drug-Coated Balloon
SRDX Stock Dips Despite the Launch of Pounce XL Thrombectomy System